Wedbush Reaffirms “Outperform” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)
Wedbush restated their outperform rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) in a research note released on Tuesday,Benzinga reports. Wedbush currently has a $18.00 price target on the stock. ARTV has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target […]
More Stories
Jessica Biel Bio: Net Worth, Career, and Personal Life
Jessica Biel has built a notable career in Hollywood. She began as a teenage television star and has since moved...
Why the Bakken Remains One of America’s Most Important Oil-Producing Regions
When most Americans think about domestic oil production, Texas probably comes to mind first. But more than a thousand miles...
Is A Different World Season 2 Renewed? Release Date, Episodes & More
Finished watching the first season of A Different World! Now searching for the renewal status and more details about A...
The Gentlemen Season 2 is Airing: Know About the Plot, Episodes, and Cast
Eddie has returned with season 2 of The Gentlemen. This time, his appearance and costumes reflect his new life as...
LEGO ONE PIECE is Live! Where to Watch and Full Cast Updates
Good news for Straw Hats fans who were waiting for the release of LEGO ONE PIECE Season 3. No, its...
Rebel Moon 3: Release Date, Cast Members, and Production Details
Zack Snyder has finally spoken about the release of Rebel Moon 3 after the release of the second sequel in...